Why Might I Still Feel Hungry On A GLP-1?

If you have started a GLP-1 medication such as semaglutide or tirzepatide and you are still feeling hungry, you are not alone. Many people across the UK experience this frustration, especially in the early weeks of treatment. Understanding why this happens and what you can do about it is the key to making your weight loss journey a success.

Table of Contents

• How GLP-1 Medications Suppress Appetite
• The Role of Dose Titration in Hunger Control
• How Food Choices Can Undermine GLP-1 Effects
• Emotional and Psychological Hunger on GLP-1
• Sleep, Stress, and the Hunger Hormone Connection
• Why Might I Still Feel Hungry on a GLP-1: Practical Solutions
• GLP-1 Hunger Factors at a Glance
• Key Takeaways
• When to Seek Professional Advice
• Scientific References
• FAQs

How GLP-1 Medications Suppress Appetite

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in your gut after eating. When you eat, your gut releases GLP-1 to signal to your brain that you are full, slow gastric emptying, and reduce appetite. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) mimic or amplify this hormone to help people eat less and lose weight more consistently over time.

These medications work primarily on the hypothalamus, the brain's hunger control centre, and on the vagus nerve, which carries satiety signals from the gut. By activating GLP-1 receptors in these areas, the drugs reduce the drive to seek food and slow down how quickly the stomach empties. This is why many people find that small portions leave them feeling fuller for much longer than before starting treatment.

However, the human appetite system is genuinely complex. GLP-1 receptors are one part of a much larger network. Hunger is influenced by ghrelin, leptin, cortisol, insulin, dopamine, and many other hormones and neurotransmitters. This is precisely why understanding why might I still feel hungry on a GLP-1 requires looking beyond the medication itself and considering the whole picture of your physical and mental health.

• GLP-1 activates receptors in the hypothalamus to reduce appetite signals
• Gastric emptying is slowed, making meals feel more satisfying for longer
• Multiple hunger hormones exist beyond GLP-1 pathways
• Individual variation in receptor sensitivity may affect response

The Role of Dose Titration in Hunger Control

One of the most common and overlooked reasons for persistent hunger on GLP-1 treatment is simply that the dose has not yet reached a therapeutically effective level. Semaglutide and tirzepatide are both introduced at a very low starting dose that is gradually increased over several weeks or months. This titration schedule exists to reduce the risk of side effects such as nausea and vomiting, not to provide maximum appetite suppression.

For example, Wegovy (semaglutide for weight management) starts at 0.25 mg weekly and increases to a maintenance dose of 2.4 mg weekly over a period of approximately sixteen to twenty weeks. At the starting dose, many patients report little change in hunger. It is typically not until the mid-to-higher doses that appetite suppression becomes noticeably significant.

In 2026, updated prescribing guidance in the UK continues to emphasise patience during the titration phase. Your prescriber will not rush you through dose increases if you are experiencing side effects. The key message here is that persistent hunger during your first four to eight weeks on a GLP-1 medication is often expected and entirely normal. Many patients find the hunger resolves significantly once they reach or approach their maintenance dose.

• Starter doses are intentionally low to protect against nausea
• Meaningful appetite suppression often begins at mid-range doses
• Full effects may take four to five months on a standard titration schedule
• Contact your prescriber if titration feels too slow for your needs
• Never increase your dose without professional guidance

How Food Choices Can Undermine GLP-1 Effects

Even when your GLP-1 medication is working well physiologically, the wrong food choices can undermine it significantly. Ultra-processed foods, liquid calories, and high-sugar snacks are specifically engineered to bypass your natural satiety signals. They are often referred to as hyper-palatable foods because they stimulate dopamine release in ways that override fullness cues — including those generated by GLP-1 receptor activation.

Liquid calories are a particularly overlooked culprit. Smoothies, protein shakes, fruit juices, fizzy drinks, alcohol, and even milky coffees can contribute substantial caloric intake without triggering the same fullness signals that solid food does. If your meal volume appears small but you are drinking calorie-dense beverages throughout the day, your GLP-1 medication cannot fully compensate for that intake.

Protein and dietary fibre are two of the most powerful allies you have when taking a GLP-1 medication. High-protein foods such as chicken, eggs, Greek yoghurt, legumes, and fish take longer to digest, promote the release of additional satiety hormones, and preserve muscle mass during weight loss. Fibre-rich foods, including vegetables, oats, lentils, and wholegrains, slow digestion and help you feel fuller for longer. Prioritising these food groups can make a significant and measurable difference to how satisfied you feel between meals. If hunger after eating is a recurring issue, reviewing your diet quality with a registered dietitian or your prescribing team can be genuinely transformative.

• Ultra-processed foods override GLP-1 satiety signals via dopamine pathways
• Liquid calories do not trigger the same fullness response as solid food
• High-protein meals extend satiety and support muscle preservation
• Dietary fibre slows digestion and supports gut hormone release
• Alcohol stimulates appetite and adds empty calories

Emotional and Psychological Hunger on GLP-1

Physical hunger and emotional hunger are two very different experiences, and GLP-1 medications predominantly address physical hunger. If you have a long-standing habit of eating in response to stress, boredom, loneliness, anxiety, or low mood, your medication is unlikely to fully eliminate that drive. This is not a failure of the medication. It reflects the reality that emotional eating is a psychological behaviour rooted in learned associations, not purely a hormonal imbalance.

Emotional hunger tends to come on suddenly, feels specific (you crave something comforting, not just any food), and often continues past the point of physical fullness. It is also frequently followed by guilt or discomfort. Physical hunger, by contrast, develops gradually, responds to any available food, and subsides once you have eaten an appropriate portion. Learning to distinguish between the two is an important skill for anyone on a weight management programme.

Cognitive behavioural techniques, mindful eating practices, and working with a therapist or health coach alongside your GLP-1 treatment can deliver significant results. Many NHS and private weight management programmes now incorporate psychological support alongside pharmacological treatment, recognising that behaviour change is an essential component of long-term success. If emotional eating is a significant driver of your hunger, raising this with your prescriber is a brave and clinically important step.

• GLP-1 medications primarily address hormonal, not psychological, hunger
• Emotional eating is driven by learned behaviour and dopamine reward systems
• Mindful eating techniques help distinguish physical from emotional hunger
• Therapy and coaching can be highly effective alongside medication

Sleep, Stress, and the Hunger Hormone Connection

If you are regularly sleeping fewer than six hours per night or living with chronic stress, your hunger levels will almost certainly be elevated regardless of what medication you are taking. This is because sleep deprivation and psychological stress both significantly increase ghrelin, often called the hunger hormone, while simultaneously reducing leptin, the hormone responsible for making you feel satisfied. The result is a powerful and biologically driven urge to eat, particularly high-calorie and high-sugar foods.

Research consistently shows that even one night of poor sleep can increase caloric intake the following day by several hundred calories. Over the course of a week, this can be more than enough to offset the caloric deficit created by your GLP-1 medication. Stress compounds this further by elevating cortisol, which promotes fat storage, particularly around the abdomen, and independently stimulates appetite through its effects on the hypothalamus.

Addressing sleep and stress is therefore not optional when it comes to making your GLP-1 treatment work effectively. Practical steps include establishing a consistent sleep schedule, reducing screen exposure before bed, using relaxation techniques such as breathing exercises or progressive muscle relaxation, and identifying sources of ongoing stress that can be modified or managed. These changes do not need to be dramatic. Even modest improvements in sleep quality can produce measurable reductions in ghrelin levels and noticeable improvements in appetite control.

• Sleep deprivation raises ghrelin and lowers leptin, increasing hunger significantly
• Cortisol from chronic stress stimulates appetite and promotes fat storage
• Even one poor night of sleep can increase the following day's caloric intake
• Seven to nine hours of quality sleep supports optimal hormone balance
• Stress management techniques directly improve appetite regulation

Why Might I Still Feel Hungry on a GLP-1: Practical Solutions

Why might I still feel hungry on a GLP-1 is a question that has several evidence-based answers, and the good news is that most of them have practical, achievable solutions. The most important first step is identifying which factor or combination of factors is most relevant to your situation. Not everyone who feels hungry on a GLP-1 is experiencing the same problem, and a one-size-fits-all solution is rarely effective.

Start by keeping a food and mood diary for one to two weeks. Record not just what you eat but when, how hungry you felt before eating, how satisfied you felt afterwards, and what your emotional state was at the time. This simple exercise frequently reveals patterns that are not apparent in day-to-day life. Common findings include eating late at night when physical hunger is low but emotional hunger is high, relying on calorie-dense snacks between meals, or skipping breakfast and then overeating later in the day.

From a dietary perspective, building every meal around a source of lean protein, a generous serving of vegetables, and a portion of wholegrains or legumes is one of the most effective strategies. Aim for three structured meals per day rather than frequent small snacks, as this allows your GLP-1 medication to work optimally with your natural satiety cycles. Drinking at least 1.5 to 2 litres of water daily also helps, as thirst is frequently mistaken for hunger. If you have reviewed your diet, sleep, and stress levels and are still struggling with hunger at your current dose, speak to your prescribing pharmacist about whether a dose review would be appropriate for your treatment plan.

• Keep a food and mood diary to identify hunger patterns and triggers
• Structure meals around protein, vegetables, and fibre-rich carbohydrates
• Drink 1.5 to 2 litres of water daily to prevent confusing thirst with hunger
• Aim for three structured meals rather than frequent grazing
• Discuss a dose review with your prescriber if hunger persists at your current level

GLP-1 Hunger Factors at a Glance

Cause of Persistent Hunger	Why It Happens	What You Can Do	When to Involve a Prescriber
Low starter dose	Titration keeps initial doses below therapeutic appetite-suppressing levels	Be patient; follow your titration schedule	If hunger is severe and affecting adherence
Ultra-processed food intake	Hyper-palatable foods bypass GLP-1 satiety signals via dopamine	Switch to whole foods, high protein, high fibre meals	If dietary changes are difficult without support
Liquid calories	Drinks do not trigger the same satiety response as solid food	Replace calorie-dense drinks with water, herbal tea, or black coffee	If you are unsure what counts as liquid calories
Emotional eating	Psychological hunger operates through reward pathways, not GLP-1 receptors	Try mindful eating, food diaries, therapy or coaching	If emotional eating is frequent or distressing
Poor sleep	Raises ghrelin and lowers leptin, increasing hunger hormones	Establish consistent sleep routine, limit screens before bed	If sleep problems are chronic or linked to a medical condition
High stress levels	Cortisol elevates appetite and promotes fat storage	Use breathing exercises, reduce stressors where possible	If stress is linked to anxiety disorder or workplace issues
Individual response variation	Genetic and physiological differences affect GLP-1 receptor sensitivity	Track progress carefully and report to your prescriber	If no appetite suppression by maintenance dose

Key Takeaways

• Persistent hunger on a GLP-1 is common and usually has a clear, addressable cause — it does not mean the medication is not working
• Dose titration means full appetite suppression often takes several months, particularly on semaglutide and tirzepatide schedules
• Food quality, particularly protein and fibre intake, plays a major role in how satisfied you feel on GLP-1 treatment
• Emotional eating and poor sleep are two of the most frequently underestimated factors driving ongoing hunger
• Working with your prescribing pharmacist, GP, or a registered dietitian significantly improves outcomes and helps you get the most from your medication

When to Seek Professional Advice

While some hunger during GLP-1 treatment is normal, particularly in the early weeks, there are times when it is important to reach out to a healthcare professional rather than trying to resolve things alone. If you have reached your maintenance dose and are still experiencing significant hunger with no progress on your weight loss goals, a clinical review is warranted. Your prescriber may consider adjusting your dose, switching medication, or exploring whether an underlying condition such as thyroid dysfunction or insulin resistance is affecting your response.

You should also seek professional advice if your hunger is accompanied by other symptoms such as fatigue, mood changes, increased thirst, or unexpected weight gain, as these may indicate a separate medical issue that requires attention. If emotional eating is significantly affecting your quality of life or relationship with food, a referral to a psychologist or registered dietitian specialising in eating behaviour can be genuinely life-changing.

In 2026, UK prescribers are increasingly offering combined pharmacological and behavioural support for patients on weight loss medications. If your current service does not include this, it is entirely appropriate to ask for it. You deserve a treatment plan that addresses all the dimensions of hunger, not just the physiological ones. Do not hesitate to contact your prescribing team at Cured Pharmacy for a personalised review of your treatment progress.

Scientific References

1. National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Technology Appraisal TA875. NICE, 2023. [Accessed 12 August 2026]
2. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. The Lancet. 2021;396(10265):1800–1812. [Accessed 12 August 2026]
3. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Annals of the New York Academy of Sciences. BMJ. 2022. [Accessed 12 August 2026]
4. NICE Guideline NG28: Type 2 diabetes in adults: management, National Institute for Health and Care Excellence, 2015 (updated 2022) [Accessed 12 August 2026]
5. Ozempic 0.5mg, 1mg and 2mg solution for injection Summary of Product Characteristics, Novo Nordisk, Electronic Medicines Compendium, 2023 [Accessed 12 August 2026]
6. Blundell J et al., 'Effects of once-weekly semaglutide on appetite, energy intake, energy expenditure, gastric emptying, and body composition in subjects with obesity', Diabetes, Obesity and Metabolism, 2017 [Accessed 12 August 2026]
7. Diabetes UK position statement on weight management medications including GLP-1 receptor agonists, Diabetes UK, 2023 [Accessed 12 August 2026]
8. Semaglutide monograph, British National Formulary, NICE/BNF, 2024 [Accessed 12 August 2026]
9. Wilding JPH et al., 'Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial)', The Lancet, 2021 [Accessed 12 August 2026]

Frequently Asked Questions

How long does it take for a GLP-1 to suppress appetite?

How long it takes for a GLP-1 to suppress appetite varies by individual. Most people begin noticing reduced hunger within two to four weeks of starting treatment, though full appetite suppression often becomes more apparent as the dose is gradually increased over several weeks or months of consistent use.

Is it normal to still feel hungry in the first few weeks on semaglutide?

Yes, it is completely normal to still feel hungry in the first few weeks on semaglutide. The medication is started at a low dose that is gradually increased to minimise side effects, which means full appetite suppression may not be noticeable until you reach a higher therapeutic dose during your titration schedule.

Can you take anything alongside a GLP-1 to help reduce hunger?

While you should not add medications without professional advice, you can support your GLP-1 treatment by eating high-protein, high-fibre meals, staying well hydrated, managing sleep and stress levels, and following a structured eating plan. Always speak to your prescribing pharmacist or GP before making any changes to your regimen.

What is the dose of semaglutide needed to reduce appetite effectively?

The dose of semaglutide needed to reduce appetite effectively is typically the maintenance dose, which for Wegovy is 2.4 mg weekly. Most titration schedules begin at 0.25 mg and increase every four weeks. Appetite suppression tends to improve significantly as the dose increases toward the full therapeutic maintenance level.